PAR1 agonist peptide
PAR1 agonist peptide has been studied in 1 paper since 2024: none in people yet, 1 in cells. No study of it in people or animals has been published yet. The newest paper, Sep 2, 2024: “Cell sheet produced from periodontal ligament stem cells activated by PAR1 improves osteogenic differentiation”.
1 paper studies it2 findingsUpdated
- 1 lab in 1 country
- Funders: Coordenação de Aperfeiçoamento de Pessoal de Nível Superior and 2 more
- Cells1
What did studies of PAR1 agonist peptide find?
2Studies of PAR1 agonist peptide measured 2 outcomes; the most studied are stem cell differentiation (1 study) and cellular senescence (1).
Stem cell differentiation
upin human cells1
1 study
Stem cell differentiation
upin human cells1
PAR1 agonist peptide improves stem cell differentiation in human cells.
“Also, PAR1 activation decreased senescence and improved osteogenic differentiation of CSs by increasing mineralized nodule deposition and alkaline phosphatase concentration”
Cellsin PDLSC cell sheets100 nM
Brazilian oral research
Cellular senescence
downin human cells1
1 study
Cellular senescence
downin human cells1
PAR1 agonist peptide decreases cellular senescence in human cells.
“Also, PAR1 activation decreased senescence and improved osteogenic differentiation of CSs”
Cellsin PDLSC cell sheets100 nM
Brazilian oral research